coronaviru
sarscov
inactiv
sarscov
explor
vaccin
sarscov
howev
safe
potent
adjuv
especi
effici
econom
needlefre
vaccin
alway
need
urgent
pandem
develop
safe
effect
mucos
adjuv
vaccin
prevent
emerg
infecti
diseas
sar
import
advanc
pika
stabil
deriv
poli
c
previous
report
safe
potent
adjuv
mous
model
present
studi
demonstr
intraperiton
intranas
coadministr
inactiv
sarscov
vaccin
togeth
improv
poli
c
deriv
induc
strong
antisarscov
mucos
system
humor
immun
respons
neutral
activ
pseudotyp
viru
although
intraperiton
immun
inactiv
sarscov
vaccin
alon
could
induc
certain
level
neutral
activ
serum
well
mucos
site
coadministr
inactiv
sarscov
vaccin
pika
adjuv
could
induc
much
higher
neutral
activ
intranas
immun
use
pika
obligatorili
induc
neutral
activ
serum
well
mucos
site
correl
mucos
iga
mucos
igg
respons
overal
pika
could
good
mucos
adjuv
candid
inactiv
sarscov
vaccin
use
possibl
futur
pandem
even
genit
tract
appropri
antisarscov
antibodi
respons
especi
divers
mucos
surfac
would
play
crucial
role
protect
mucos
transmiss
sarscov
exampl
passiv
transfer
neutral
serum
antibodi
naiv
mice
prevent
sarscov
replic
lower
respiratori
tract
follow
intranas
challeng
prophylact
administr
neutral
human
monoclon
antibodi
reduc
replic
sarscov
lung
infect
ferret
prevent
develop
sarscov
induc
macroscop
lung
patholog
besid
mucos
secretori
iga
lower
respiratori
tract
immun
protect
digest
tract
mucos
site
seem
crucial
import
given
fact
transmiss
sarscov
occur
direct
contact
droplet
viru
fecal
oral
rout
taken
togeth
report
suggest
wide
rang
humor
immun
system
divers
mucos
surfac
may
play
import
role
vaccineinduc
protect
sarscov
transmiss
mucos
immun
play
import
role
prevent
invas
pathogen
could
induc
via
system
mucos
immun
howev
immun
protocol
requir
effect
adjuv
produc
better
immun
respons
mucos
deliv
antigen
absenc
adjuv
usual
induc
either
low
undetect
antigenspecif
immun
respons
result
immun
toler
present
mucos
vaccin
approv
human
use
unit
state
elsewher
exampl
includ
oral
vaccin
mostli
compris
live
attenu
antigen
polioviru
v
cholera
salmonella
typhi
rotaviru
nasal
vaccin
influenza
viru
becom
increasingli
appar
effect
mucos
adjuv
high
prioriti
develop
effici
mucos
vaccin
synthet
dsrna
term
poli
c
found
abl
boost
immun
respons
sinc
recent
poli
c
discov
function
adjuv
interact
turn
activ
pathway
result
stabl
matur
dc
activ
nk
cell
longertim
surviv
activ
cell
vitro
ichinoh
et
al
report
intranas
vaccin
hemaglutinin
ha
adjuv
poli
c
induc
protect
influenza
viral
infect
mice
brian
r
sloat
also
show
nasal
immun
anthrax
pa
plu
poli
c
enhanc
product
mucos
system
immun
therefor
poli
c
repres
anoth
potenti
adjuv
howev
poli
c
unsuit
potenti
adjuv
toxic
rapidli
hydrolyz
human
use
alon
sever
poli
c
deriv
suggest
poli
iclc
poli
c
contain
polyllysin
carboxymethylcellulos
minim
observ
defici
poli
c
pika
particular
deriv
poli
c
compris
kanamycin
calcium
chlorid
specif
igg
respons
mice
recent
studi
also
show
pika
provid
broadspectrum
prophylaxi
number
influenza
virus
coadministr
pika
poorli
immunogen
subunit
vaccin
lead
antigen
spare
quantit
qualit
improv
immun
respons
achiev
unadjuv
vaccin
mice
present
studi
demonstr
intraperiton
intranas
coadministr
product
inactiv
formaldehyd
pika
improv
adjuv
formul
compris
deriv
poli
c
kanamycin
calcium
chlorid
manufactur
complianc
good
manufactur
practic
newbiom
pika
pte
ltd
singapor
femal
balbc
mice
week
age
purchas
hubei
cdc
maintain
spf
environ
throughout
experi
mice
immun
either
intranas
intraperiton
ip
rout
inactiv
sarscov
inactiv
sarscov
plu
indic
dose
pika
mice
immun
pb
serv
neg
control
protocol
intranas
immun
requir
mice
anesthet
slightli
sodium
pentobarbit
held
invert
nose
droplet
vaccin
appli
extern
nare
complet
inhal
intranas
immun
reagent
suspend
pb
individu
mice
receiv
inocul
five
time
min
rest
interv
inocul
total
volum
intraperiton
immun
vaccin
composit
adjust
pb
consist
dose
mous
receiv
three
immun
interv
immun
sampl
collect
two
week
final
immun
previous
describ
blood
sampl
collect
retroorbit
plexu
punctur
saliva
obtain
intraperiton
inject
carbamylcholin
chlorid
vagin
tract
individu
mice
wash
pb
three
time
total
volum
remov
fece
small
intestin
tissu
weigh
cut
small
piec
mix
pb
mg
small
intestin
pb
rock
h
collect
lung
wash
fluid
trachea
expos
surgic
oral
portion
trachea
clamp
syring
equip
needl
insert
trachea
pb
inject
peripher
airway
five
cycl
aspir
inject
repeat
centrifug
min
supernat
sampl
collect
store
antibodi
detect
antisarscov
titer
sampl
determin
elisa
specif
antibodi
neutral
test
carri
pseudotyp
sarscov
produc
qu
et
al
describ
previous
slight
modif
western
blot
assay
carri
accord
protocol
molecular
clone
briefli
segment
spike
protein
sarscov
express
vitro
name
separ
sdspage
stack
polyacrylamid
gel
combin
separ
gel
separ
protein
transfer
nitrocellulos
membran
h
current
block
bsa
pb
h
statist
signific
differ
group
calcul
student
ttest
two
group
tukey
test
use
anova
three
group
differ
consid
signific
p
optim
concentr
pika
adjuv
identifi
immun
mice
intraperiton
intranas
pika
mix
inactiv
sarscov
antigen
abil
induc
secretori
fig
wherea
increas
siga
titer
could
induc
pika
coadministr
antigen
intranas
interperiton
respect
howev
specif
siga
titer
could
detect
lung
wash
fluid
fig
although
neutral
activ
could
detect
lung
fig
one
concern
lung
also
assay
sarscov
specif
igg
pool
mucos
sampl
well
serum
sampl
result
summar
fig
pika
could
increas
specif
igg
respons
intestin
saliva
vagina
lung
fig
black
bar
determin
dilut
sampl
use
elisa
bar
repres
arithmet
mean
titer
individu
group
se
statist
signific
differ
group
calcul
use
transform
data
elisa
mean
titer
student
ttest
two
group
tukey
test
use
anova
three
group
ag
inactiv
sarscov
alon
agpika
inactiv
sarscov
plu
pika
approach
could
help
elicit
hiv
immunogen
specif
iga
igg
respons
vagin
fecal
saliva
sampl
parenter
administ
viruslik
particl
even
elicit
efficaci
infect
preinvas
diseas
previous
uninfect
individu
determin
correl
neutral
activ
antibodi
serum
mucos
secret
igg
iga
respons
serum
mucos
secret
test
studi
neutral
activ
detect
lung
sampl
three
group
mice
specif
igg
iga
could
detect
fig
antibodi
analysi
also
indic
specif
igg
specif
iga
respons
mucos
site
correl
neutral
activ
possibl
mucos
igg
could
also
play
import
role
contribut
neutral
activ
mucos
site
propos
serum
igg
induc
parenter
immun
could
find
way
mucosa
exert
protect
effect
rel
high
concentr
igg
seen
particular
mucos
site
may
reflect
combin
constitut
transcellular
paracellular
transport
system
compart
specif
transport
mechan
therefor
detect
igg
respons
mucos
site
also
use
evalu
mucos
immun
respons
relat
neutral
activ
sarscov
infect
occur
mucos
surfac
lung
digest
surfac
even
vagin
surfac
induct
neutral
activ
could
block
viru
attach
infect
import
sarscov
prevent
studi
show
pika
effect
induc
neutral
activ
mucos
site
coadminist
intraperiton
intranas
immun
fig
intranas
immun
appear
less
effect
intraperiton
immun
elicit
neutral
activ
even
adjuv
pika
may
partial
result
certain
loss
vaccin
antigen
dilut
mucos
secret
captur
mucu
gel
attack
proteas
nucleas
exclus
epitheli
cell
deliv
mucos
rout
howev
note
intranas
immun
could
induc
much
higher
specif
iga
respons
intraperiton
immun
mani
studi
alreadi
demonstr
mucos
siga
inhibit
viral
infect
via
immun
exclus
intracellular
viru
neutral
transepitheli
transport
immun
complex
even
rotaviru
iga
monoclon
antibodi
lack
neutral
activ
protect
mice
infect
rotaviru
via
intracellular
neutral
mechan
sarscovspecif
siga
may
also
provid
similar
kind
protect
sarscov
invas
mucos
site
absenc
classic
neutral
activ
true
vitro
neutral
activ
may
reflect
partial
correl
protect
effect
immun
respons
adjuvant
pika
may
mostli
deriv
main
compon
poli
c
howev
adjuv
mechan
poli
c
clearli
understood
yet
although
believ
relat
dsrna
structur
mediat
immun
respons
invivo
presenc
viral
dsrna
trigger
cellular
immun
respons
viral
infect
activ
dsrnadepend
enzym
includ
pkr
ifninduc
synthasernas
l
system
addit
mammalian
recogn
viral
dsrna
lead
activ
product
type
interferon
serv
bridg
innat
adapt
immun
system
takeshi
develop
applic
adjuv
human
use
prioriti
safeti
ct
potent
known
mucos
adjuv
advers
side
effect
nasal
discharg
human
determin
mucos
adjuvant
new
adjuv
pika
deriv
poli
c
poli
c
toxic
human
rapidli
hydrolyz
despit
strong
adjuvant
pika
improv
adjuv
formul
togeth
pika
well
formul
stabl
safe
adjuv
summari
demonstr
intraperiton
intranas
administr
pika
adjuv
significantli
rais
humor
immun
respons
neutral
activ
sarscov
serum
mucos
site
therefor
pika
good
adjuv
candid
also
use
mucos
vaccin
